Common questions about Gocovri (FAQ)
Q: Is Gocovri used for anything other than Parkinson's disease?
A: The specific extended-release medicine, Gocovri, is officially approved for the treatment of dyskinesia and 'off' episodes in Parkinson's disease patients who are already taking levodopa-based therapy. While the active substance (amantadine) is used in other formulations for other purposes, Gocovri’s regulatory approval is limited to these specific Parkinson’s complications.
Q: Is it true that Gocovri can cause insomnia or sleep issues?
A: Regulatory documents list 'trouble with sleeping' (insomnia) as one of the commonly observed side effects. Other central nervous system effects, such as confusion or trouble concentrating, are also noted.
Q: What does 'dyskinesia' mean in simple terms?
A: Dyskinesia refers to involuntary, erratic, or twisting movements of the face, arms, legs, or trunk. This condition is a motor complication that involves involuntary, erratic, or twisting movements.
Q: Is Gocovri suitable for elderly patients?
A: The medicine is approved for use in adults. However, official information indicates that caution is required when prescribing to older adults. This is due to a higher likelihood of age-related changes in kidney function and an increased risk of side effects like falls, dizziness, and hallucinations in this population.
Q: Why is Gocovri specifically approved for dyskinesia in Parkinson's patients?
A: Gocovri is classified as an N-methyl-D-aspartate (NMDA) receptor antagonist. It was approved based on clinical trials that successfully demonstrated its ability to reduce levodopa-induced dyskinesia (LID) and motor 'off' time in patients with Parkinson's disease.
Q: Is Gocovri considered a long-term treatment?
A: Gocovri is indicated for a condition—the treatment of dyskinesia and 'off' episodes in Parkinson's disease—that typically requires chronic, ongoing management. However, controlled clinical studies evaluating the effects of the medicine only did so over a few months, and the full long-term effects are not fully established by this controlled data.
Q: What is the experience of people who have been on Gocovri for many years?
A: Official clinical trial data only evaluated the effects of the medicine in controlled studies over a period of a few months. The long-term effects of the medication on patients are not fully established by this controlled research.
Q: Is Gocovri used in the early or late stages of Parkinson's disease?
A: The medicine is approved for a specific patient group: those experiencing involuntary movements (dyskinesia) and 'off' episodes while on levodopa-based therapy. These motor complications typically begin after the disease has progressed past the initial stages.
Q: Does the official information mention Gocovri causing feelings of confusion or disorientation?
A: The official FDA label lists confusion as a common side effect (reported in 5% or more of patients in studies). Confusion can also be a symptom associated with sudden dose reduction or withdrawal of the medication.
Q: What are the potential effects of Gocovri if it's taken during the day instead of at night?
A: The medication is designed to be taken at bedtime, as stated in the administration instructions. Taking the capsule at a different time than prescribed may disrupt the controlled-release profile. This may potentially increase the risk of daytime central nervous system effects, such as excessive sleepiness or falling asleep during normal activities.
Q: Can Gocovri cause problems with vision or eyes?
A: The FDA label mentions that blurred vision and decreased vision are possible side effects. A rare but serious risk is corneal edema (swelling of the clear covering over the eye), which has been associated with sudden or progressive vision loss.
Q: How quickly do people usually start to notice the effects of Gocovri?
A: The clinical pharmacology data indicates that the medication takes approximately four days to reach a steady-state level in the body. This steady-state concentration is necessary for the drug to provide consistent effects throughout the day.
Q: Is it possible to become dependent on Gocovri?
A: The official product information states that rapid dose reduction or abrupt discontinuation of the medicine must be avoided. Stopping the medicine too quickly may cause severe symptoms, including a potentially serious syndrome resembling neuroleptic malignant syndrome (NMS).
Q: Can people taking Gocovri safely drive a car?
A: Official patient information states that engaging in activities like driving or operating machinery is not recommended until a person knows exactly how the medicine affects them. This is due to the risk of excessive sleepiness (somnolence) and dizziness.
Q: Is it normal to have vivid dreams when starting Gocovri?
A: The FDA label lists 'nightmares' and 'abnormal dreams' as potential side effects. Patients in clinical trials reported these effects.
Q: Does Gocovri have a risk of causing a serious allergic reaction?
A: Allergic reactions are a possible side effect of the medicine. Signs of a serious reaction may include swelling of the face, lips, tongue, or throat.
Q: Are there any known interactions with herbal supplements and Gocovri?
A: Official patient information advises telling a healthcare provider about all medicines, including prescription, over-the-counter medicines, and herbal supplements. This is necessary to check for any potential interactions that could affect how the medicine works or increase the risk of side effects.
Q: Is Gocovri linked to any skin conditions or rashes?
A: Skin conditions are a documented side effect. These include general skin rash and, more specifically, purplish red or blotchy spots on the skin known as livedo reticularis.
Q: Does Gocovri interact with any mood stabilizers or antidepressants?
A: The medicine may have documented interactions with specific classes of medicines, including certain antidepressants (such as MAOIs or TCAs). Combining these medications can increase side effects, toxicity, or affect blood pressure.
Q: Can patients with heart conditions safely use Gocovri?
A: Patients with a history of edema (swelling) or congestive heart failure (CHF) should be closely monitored. The official information states that patients with a history of these conditions should be closely monitored.
Q: Are there any differences in how Gocovri affects men versus women?
A: Clinical trial data published in the FDA label shows differences in the frequency of certain side effects by gender. For example, dry mouth and abnormal dreams were reported more often in women, while dizziness and peripheral edema (swelling of the limbs) were more common in men.
Q: Can Gocovri cause changes in appetite or weight?
A: Changes in appetite are a possible side effect, including decreased or loss of appetite. Weight gain may also occur, which is often associated with fluid retention known as peripheral edema (swelling of the legs or feet).
